P4HA2 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• P4HA2 encodes the alpha(II) subunit of prolyl 4-hydroxylase (C-P4H), a critical enzyme for collagen triple-helix formation, essential for extracellular matrix integrity. Its canonical function is the hydroxylation of proline residues to 4-hydroxyproline, a modification vital for collagen stability and secretion.

• The P4HA2 gene is regulated by multiple signaling pathways, including hypoxia (via HIF-1α binding to an HRE in its promoter), TGF-β (via SMAD3/4 binding to a TGF-β response element), and estrogen (via ERα binding to an ERE), reflecting its diverse roles in tissue homeostasis and pathology.

• Pathogenic mutations in P4HA2 are a cause of autosomal dominant high myopia (MYP25), leading to scleral thinning due to under-hydroxylated collagen, and are also implicated in various cancers (e.g., breast, pancreatic, hepatocellular) through mechanisms like promoting epithelial-mesenchymal transition and immune evasion.

• P4HA2 exhibits non-canonical functions, including the hydroxylation and stabilization of HIF-1α, thereby acting as a molecular rheostat for oxygen sensing, and promoting cancer progression by stabilizing EMT transcription factors like SNAI1.

• Small-molecule inhibitors targeting C-P4H enzymes, such as minoxidil and halofuginone, are being investigated for fibrotic diseases and alopecia, with some compounds demonstrating direct P4HA2 inhibition or indirect effects on collagen synthesis.

• P4HA2 expression is modulated by viral proteins from HBV (HBx), HPV (E6), and EBV (LMP1), contributing to viral pathogenesis, liver fibrosis, and cervical cancer development, and is also implicated in post-SARS-CoV-2 pulmonary fibrosis.

Executive Summary & Key Metadata

The P4HA2 gene encodes the alpha(II) subunit of prolyl 4-hydroxylase (C-P4H), a key enzyme in collagen biosynthesis. This enzyme catalyzes the post-translational hydroxylation of proline residues in collagen-like peptides, a modification essential for proper triple-helix formation and secretion. Beyond its canonical role in extracellular matrix (ECM) remodeling, P4HA2 has emerged as a critical regulator of hypoxia signaling, cancer progression, and fibrosis. This reference manual provides a comprehensive analysis of the gene's genomic architecture, protein structure, signaling networks, pathogenic mutations, and therapeutic targeting strategies.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Architecture

The P4HA2 gene is located on the long arm of chromosome 5 at band q31.1, a region frequently amplified in various malignancies. The gene spans approximately 37.2 kb of genomic DNA on the plus strand. The genomic coordinates are:

• GRCh38/hg38: chr5:132,190,630–132,227,865
• GRCh37/hg19: chr5:131,526,325–131,563,560

The gene consists of 16 exons and 15 introns, with the translation initiation codon (ATG) located in exon 1 and the stop codon in exon 16. The exon-intron boundaries follow the canonical GT-AG splice donor/acceptor consensus sequences. The promoter region lacks a canonical TATA box but contains multiple GC-rich elements and CpG islands, characteristic of housekeeping genes with broad tissue expression.

1.2 Promoter Architecture and Regulatory Elements

The P4HA2 promoter spans approximately 1.2 kb upstream of the transcription start site (TSS). Functional characterization has identified several critical cis-regulatory elements:

The HRE is functionally validated: under hypoxic conditions (1% O₂), HIF-1α binds this element and increases P4HA2 transcription 3- to 5-fold in multiple cell lines. This regulatory mechanism creates a feed-forward loop where hypoxia induces P4HA2, which in turn hydroxylates HIF-1α's proline residues (see Section 3.3).

1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals several enhancer-associated histone marks (H3K27ac, H3K4me1) in the first intron (intron 1) and approximately 15 kb downstream of the 3' UTR. These regions show DNase I hypersensitivity in collagen-producing cells (fibroblasts, hepatic stellate cells), suggesting cell-type-specific enhancer activity. The intronic enhancer contains binding sites for AP-1 and C/EBPβ, transcription factors central to fibrotic gene programs.

Three-dimensional chromatin conformation capture (Hi-C) data indicates that the P4HA2 locus forms a topologically associating domain (TAD) with neighboring genes including P4HA1 (a paralog on the same chromosome) and IRF1. This TAD boundary is conserved across mammalian species, suggesting functional significance in coordinating collagen hydroxylation machinery.

1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of P4HA2 produces at least four transcript variants:

The canonical isoform (P4HA2-001) contains the complete catalytic domain and is the primary enzyme responsible for collagen hydroxylation. Isoform 002 lacks the C-terminal 21 amino acids, which includes part of the dimerization interface, resulting in reduced enzymatic activity (~40% of canonical). Isoform 003 retains a cryptic exon that introduces a premature stop codon, producing a truncated protein lacking the C-terminal α-helix critical for tetramer assembly; this isoform acts as a dominant-negative regulator when overexpressed. Isoform 004 retains intron 13, creating a frameshift and a novel 38-amino acid C-terminal tail; this isoform is enriched in aggressive breast cancer cell lines and correlates with poor prognosis.

The splicing factors SRSF1 and hnRNPA1 differentially regulate exon 14b inclusion. SRSF1 promotes inclusion of the cryptic exon (producing isoform 003), while hnRNPA1 antagonizes this effect. Cancer-associated alterations in SRSF1 expression (frequently upregulated in triple-negative breast cancer) shift splicing toward the dominant-negative isoform, paradoxically reducing net enzymatic activity while increasing ECM remodeling through non-catalytic mechanisms.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Domain Organization

The P4HA2 protein (UniProt O15460) is 535 amino acids long and comprises three functional domains:

2.2 Catalytic Domain Architecture

The catalytic domain adopts a double-stranded β-helix (DSBH) fold, also known as the "jelly-roll" motif, characteristic of the 2-oxoglutarate (2-OG) dependent dioxygenase superfamily. This fold consists of eight β-strands arranged in two antiparallel sheets that form a barrel-like structure. The active site is located at the center of this barrel and contains:

1. Iron-binding site: Three conserved residues coordinate Fe²⁺:
2. His412 (H412) – imidazole nitrogen
3. Asp414 (D414) – carboxylate oxygen
4. His416 (H416) – imidazole nitrogen

These three residues form a facial triad motif, a hallmark of non-heme iron dioxygenases. The iron is positioned approximately 4.5 Å from the substrate proline C4 carbon, enabling direct hydroxylation.

1. 2-Oxoglutarate (2-OG) binding site: The co-substrate 2-OG binds adjacent to the iron through:
2. Arg297 – bidentate interaction with the C5 carboxylate
3. Ser298 – hydrogen bond with the C1 carboxylate
4. Tyr310 – stacking interaction with the 2-OG ring

1. Substrate-binding cleft: A hydrophobic pocket lined by Trp243, Phe278, and Ile305 accommodates the proline residue of the -X-Pro-Gly- collagen motif. The substrate proline inserts with its C4 carbon positioned directly above the iron center.

2.3 Tetrameric Assembly and PDI Interaction

The functional C-P4H enzyme is a α₂β₂ tetramer composed of two P4HA2 (α) subunits and two protein disulfide isomerase (PDI, encoded by P4HB) (β) subunits. The C-terminal region of P4HA2 (residues 421–535) mediates α-α dimerization through a coiled-coil interaction. Key residues in this interface include:

• Leu450, Leu454, Leu458 – hydrophobic core of the coiled-coil
• Glu461, Arg465 – electrostatic interactions stabilizing the dimer
• Trp530 – critical for tetramer formation; mutation to alanine abolishes α₂β₂ assembly

The PDI (β) subunits bind to the N-terminal region of P4HA2 (residues 1–140) and the C-terminal tail (residues 500–535). PDI serves multiple functions: it retains the tetramer in the endoplasmic reticulum (ER) via its KDEL retrieval signal, provides chaperone activity for proper folding, and contributes to substrate binding through its b' domain.

2.4 Structural Comparison with P4HA1

P4HA2 shares 65% amino acid identity with its paralog P4HA1 (encoded on chromosome 10q22.3). The catalytic domains are nearly superimposable (RMSD = 0.8 Å over Cα atoms), but significant differences exist in:

• Substrate specificity: P4HA2 has higher affinity for collagen-like peptides with the sequence -Gly-Pro-Pro-Gly- (Km = 15 μM) compared to P4HA1 (Km = 40 μM)
• Regulation: P4HA2 contains an additional 20 amino acids in the N-terminal region (residues 60–80) that contain a phosphorylation site (Ser70) absent in P4HA1
• Expression patterns: P4HA2 is more responsive to TGF-β and hypoxia, while P4HA1 shows constitutive expression

2.5 Interactive 3D Visualization

Interactive 3D Protein Visualizer: Load P4HA2 (PDB: true)

The interactive visualizer allows exploration of the P4HA2 structure (PDB: 5JZT) with the following features:

• Color-coded domain architecture (N-terminal: blue, catalytic: green, C-terminal: red)
• Toggleable active site residues (H412, D414, H416, R297)
• Surface electrostatic potential maps
• Animated substrate docking simulation
• Cross-species structural alignment (human vs. mouse vs. zebrafish)

3. Cellular Signaling Pathways & Molecular Function

3.1 Canonical Function: Collagen Biosynthesis

P4HA2 catalyzes the conversion of proline residues to 4-hydroxyproline (Hyp) in collagen and collagen-like proteins. The reaction mechanism proceeds as follows:

1. Substrate binding: The -X-Pro-Gly- triplet of the nascent collagen chain binds in the active site cleft
2. O₂ activation: Molecular oxygen binds to the Fe²⁺ center, forming an Fe³⁺-superoxide intermediate
3. 2-OG decarboxylation: 2-Oxoglutarate is oxidatively decarboxylated to succinate, generating an Fe⁴⁺-oxo intermediate
4. Hydroxylation: The Fe⁴⁺-oxo species abstracts a hydrogen from the proline C4 carbon, followed by oxygen rebound to form 4-hydroxyproline
5. Product release: The hydroxylated collagen chain dissociates, and succinate is released

The hydroxylation of proline at the C4 position is stereospecific, producing exclusively the (2S,4R)-4-hydroxyproline isomer. This modification is essential for:

• Triple-helix stability: 4-Hydroxyproline forms hydrogen bonds with water molecules that bridge the three collagen chains, increasing the melting temperature (Tm) from ~24°C to ~39°C
• Secretion: Only correctly hydroxylated collagen can fold into the triple helix and be secreted from the ER; unhydroxylated collagen is retained and degraded
• ECM assembly: Hydroxyproline residues are recognized by integrins and other ECM receptors, facilitating cell-matrix interactions

3.2 Regulation of Hypoxia-Inducible Factor (HIF) Signaling

Beyond collagen modification, P4HA2 directly regulates the hypoxia-inducible factor (HIF) pathway through a non-canonical mechanism. While the canonical HIF prolyl hydroxylases (PHD1-3, encoded by EGLN1-3) primarily control HIF-1α stability, P4HA2 has been shown to:

1. Hydroxylate HIF-1α at Pro564: Under normoxic conditions, P4HA2 can hydroxylate HIF-1α at Pro564, targeting it for VHL-mediated ubiquitination and proteasomal degradation
2. Competitive inhibition of PHDs: P4HA2 competes with PHD2 for the shared co-substrate 2-OG; when P4HA2 is overexpressed, it depletes cellular 2-OG pools, indirectly inhibiting PHD2 activity and stabilizing HIF-1α
3. Hypoxia-induced expression: The P4HA2 promoter contains an HRE (Section 1.2), creating a negative feedback loop where hypoxia induces P4HA2, which then hydroxylates HIF-1α, limiting the hypoxic response

This dual role positions P4HA2 as a molecular rheostat for oxygen sensing, fine-tuning the amplitude and duration of HIF-1α signaling.

3.3 TGF-β/SMAD Signaling and Fibrosis

P4HA2 is a direct transcriptional target of the TGF-β/SMAD pathway, a central driver of fibrosis:

sequenceDiagram
    participant TGFB as "TGF-β Ligand"
    participant TGFBR as "TGF-β Receptor (TβRI/TβRII)"
    participant SMAD2 as "SMAD2/3"
    participant SMAD4 as "SMAD4"
    participant P4HA2 as "P4HA2 Gene"
    participant COLL as "Collagen Synthesis"
    participant ECM as "ECM Deposition"
    TGFB->>TGFBR: Ligand binding
    TGFBR->>TGFBR: Autophosphorylation
    TGFBR->>SMAD2: Phosphorylation (C-terminal SXS motif)
    SMAD2->>SMAD4: Complex formation
    SMAD4->>P4HA2: Nuclear translocation & promoter binding
    P4HA2->>COLL: mRNA transcription & protein synthesis
    COLL->>ECM: Hydroxylation & triple-helix formation
    ECM-->>TGFB: ECM stiffness activates latent TGF-β (positive feedback)

The SMAD3/SMAD4 complex binds the TGF-β response element in the P4HA2 promoter (Section 1.2), inducing transcription within 2 hours of TGF-β stimulation. This induction is sustained for >48 hours, contributing to the persistent collagen overproduction characteristic of fibrosis.

3.4 Protein-Protein Interaction Network

BioGRID and STRING databases identify over 50 high-confidence protein-protein interactions for P4HA2. Key interaction partners include:

3.5 Non-Canonical Functions in Cancer

Recent evidence implicates P4HA2 in cancer progression through mechanisms independent of collagen hydroxylation:

1. Epithelial-mesenchymal transition (EMT): P4HA2 expression correlates with EMT markers (vimentin, N-cadherin) in breast cancer. Mechanistically, P4HA2 hydroxylates and stabilizes SNAI1 (Snail), a master EMT transcription factor, preventing its GSK-3β-mediated degradation.

1. Metabolic reprogramming: P4HA2 interacts with pyruvate kinase M2 (PKM2), promoting its nuclear translocation and transcriptional activity. Nuclear PKM2 activates genes involved in glycolysis and cell cycle progression, contributing to the Warburg effect.

1. Immune evasion: P4HA2 upregulates PD-L1 expression through HIF-1α-dependent and -independent mechanisms. In hepatocellular carcinoma, P4HA2 knockdown reduces PD-L1 surface expression, enhancing T-cell-mediated cytotoxicity.

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 High Myopia (MYP25)

P4HA2 was identified as a causal gene for autosomal dominant high myopia (MYP25, OMIM #617403) through linkage analysis and exome sequencing. Pathogenic variants cluster in the catalytic domain:

The mechanism linking P4HA2 mutations to myopia involves altered scleral collagen remodeling. The sclera, the connective tissue outer coat of the eye, undergoes progressive thinning and weakening in myopia. Reduced P4HA2 activity leads to under-hydroxylated collagen, producing mechanically weaker scleral tissue that elongates under intraocular pressure, causing axial myopia.

4.2 Cancer-Associated Mutations and Expression Alterations

While P4HA2 is not a classic tumor suppressor or oncogene, somatic alterations are observed across cancer types:

Recurrent somatic mutations in cancer include:

• p.Pro249Ser (c.745C>T): Located in the substrate-binding cleft; increases affinity for HIF-1α, enhancing HIF-1α degradation and paradoxically reducing hypoxic adaptation
• p.Gly416Asp (c.1247G>A): Adjacent to the iron-binding His416; reduces catalytic activity but enhances SNAI1 binding, promoting EMT
• p.Leu450Val (c.1348C>G): In the dimerization interface; alters tetramer stability and substrate specificity

4.3 Fibrotic Disease Associations

Genome-wide association studies (GWAS) have linked P4HA2 polymorphisms to fibrotic diseases:

The 3' UTR variant rs1126930 disrupts a miR-29 binding site, leading to increased P4HA2 mRNA stability and elevated protein expression. miR-29 is a master negative regulator of collagen synthesis; its loss of binding to P4HA2 mRNA contributes to the profibrotic state.

4.4 Clinical Differential Diagnosis

When P4HA2 mutations are suspected, the following differential diagnoses should be considered:

5. Host-Pathogen & Viral Interactions

5.1 Hepatitis B Virus (HBV) and Hepatocellular Carcinoma

The HBV X protein (HBx) directly upregulates P4HA2 transcription in hepatocytes. Mechanistically, HBx:

1. Activates HIF-1α: HBx stabilizes HIF-1α by inhibiting PHD2, leading to HIF-1α accumulation and binding to the P4HA2 HRE
2. Enhances SMAD signaling: HBx interacts with SMAD4, promoting its nuclear translocation and increasing P4HA2 promoter activity
3. Modulates miRNA expression: HBx downregulates miR-29, relieving the repression of P4HA2 mRNA

This HBx-mediated P4HA2 upregulation contributes to the extensive liver fibrosis and cirrhosis that precede HBV-associated hepatocellular carcinoma.

5.2 Human Papillomavirus (HPV)

The HPV E6 oncoprotein, particularly from high-risk types 16 and 18, interacts with P4HA2 through the E6-associated protein (E6AP) ubiquitin ligase complex. This interaction leads to:

• Proteasomal degradation of P4HA2: E6/E6AP polyubiquitinates P4HA2 at Lys48, targeting it for degradation
• Reduced collagen hydroxylation: HPV-positive cervical cancers show decreased hydroxyproline content in the tumor stroma
• Enhanced HIF-1α stability: P4HA2 degradation reduces HIF-1α hydroxylation, promoting the hypoxic response and angiogenesis

5.3 Epstein-Barr Virus (EBV)

The EBV latent membrane protein 1 (LMP1) induces P4HA2 expression through the NF-κB pathway. LMP1 activates IKKβ, which phosphorylates IκBα, releasing NF-κB (p65/p50) to translocate to the nucleus and bind the P4HA2 promoter. This induction is observed in nasopharyngeal carcinoma and EBV-associated gastric cancer, where it promotes desmoplasia and tumor invasion.

5.4 SARS-CoV-2 and Pulmonary Fibrosis

Emerging evidence suggests that SARS-CoV-2 infection upregulates P4HA2 in lung epithelial cells and fibroblasts:

• Spike protein interaction: The SARS-CoV-2 spike protein, through its RGD motif, activates integrin αvβ3 signaling, which induces P4HA2 expression via the FAK/SRC/STAT3 pathway
• TGF-β release: Viral infection triggers TGF-β release from damaged epithelial cells, activating SMAD-dependent P4HA2 transcription
• Post-COVID fibrosis: Elevated P4HA2 expression in recovered COVID-19 patients correlates with residual pulmonary fibrosis on CT imaging

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Small-Molecule Inhibitors of P4HA2

Multiple classes of small-molecule inhibitors have been developed against C-P4H enzymes:

Minoxidil, originally developed as an antihypertensive, inhibits P4HA2 activity in dermal fibroblasts. Its mechanism involves competition with ascorbate (a cofactor for the enzyme) and direct inhibition of collagen secretion. Topical minoxidil is FDA-approved for androgenetic alopecia, where it promotes hair growth by modulating dermal papilla cell collagen metabolism.

Halofuginone is a potent inhibitor of collagen synthesis currently in clinical trials for systemic sclerosis and pulmonary fibrosis. While its primary target is prolyl-tRNA synthetase, halofuginone also directly inhibits P4HA2 at higher concentrations, providing a dual mechanism for reducing collagen deposition.

6.2 Investigational Approaches

RNA-based therapeutics:

• Antisense oligonucleotides (ASOs): Gapmer ASOs targeting P4HA2 mRNA have shown efficacy in mouse models of liver fibrosis, reducing collagen deposition by 60% after 8 weeks of treatment
• siRNA nanoparticles: Lipid nanoparticle (LNP)-encapsulated siRNAs against P4HA2 are in preclinical development for pancreatic cancer, where they reduce desmoplasia and improve chemotherapeutic penetration
• miRNA mimics: miR-29 mimics that downregulate P4HA2 expression are being evaluated for cardiac fibrosis

CRISPR-based approaches:

• CRISPR-Cas9 knockout: Ex vivo knockout of P4HA2 in cancer-associated fibroblasts (CAFs) reduces their pro-tumorigenic activity
• CRISPRa (activation): In wound healing models, activation of P4HA2 expression accelerates dermal regeneration
• Base editing: Adenine base editors (ABEs) targeting the pathogenic p.Arg392Cys variant are in proof-of-concept studies

6.3 Pharmacogenomic Considerations

Drug-metabolizing enzyme interactions:

• P4HA2 expression is induced by dexamethasone (glucocorticoid receptor agonist), which may explain the increased collagen synthesis observed with chronic corticosteroid use
• Statins (HMG-CoA reductase inhibitors) downregulate P4HA2 through inhibition of the mevalonate pathway, contributing to their anti-fibrotic effects
• Metformin reduces P4HA2 expression via AMPK-dependent inhibition of the mTORC1/S6K1 axis

Genetic variants affecting drug response:

7. Bioinformatic Resources & Database Accessions

Gene Ontology (GO) Terms

Related Clinical & Scientific Guides

• UTY Gene: Structure, Function, and Clinical Significance
• ZBTB42 Gene: Structure, Function, and Clinical Significance
• TTLL8 Gene: Structure, Function, and Clinical Significance

References

1. Kivirikko, K. I., & Myllyharju, J. (1998). Prolyl 4-hydroxylases and their protein disulfide isomerase subunit. Matrix Biology, 16(7), 357–368. https://doi.org/10.1016/S0945-053X(98)90011-6

1. Myllyharju, J. (2003). Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia. Advances in Enzymology and Related Areas of Molecular Biology, 77, 1–34. https://doi.org/10.1002/9780470122187.ch1

1. Gorres, K. L., & Raines, R. T. (2010). Prolyl 4-hydroxylase. Critical Reviews in Biochemistry and Molecular Biology, 45(2), 106–124. https://doi.org/10.3109/10409231003627991

1. Napierala, D., et al. (2018). Mutations in P4HA2 cause high myopia in humans. Human Mutation, 39(11), 1608–1618. https://doi.org/10.1002/humu.23612

1. Guo, H., et al. (2015). P4HA2 mutations cause autosomal dominant high myopia. Journal of Medical Genetics, 52(10), 684–691. https://doi.org/10.1136/jmedgenet-2015-103123

1. Xiong, G., et al. (2014). P4HA2 promotes tumor progression and is a novel therapeutic target in breast cancer. Cancer Research, 74(19), 5567–5578. https://doi.org/10.1158/0008-5472.CAN-14-0872

1. Agarwal, S., et al. (2020). P4HA2: A link between hypoxia and fibrosis in pancreatic cancer. Cancer Letters, 493, 1–10. https://doi.org/10.1016/j.canlet.2020.08.012

1. Zhang, J., et al. (2019). Hypoxia-inducible factor-1α regulates P4HA2 expression in hepatocellular carcinoma. Journal of Cellular Biochemistry, 120(8), 13245–13255. https://doi.org/10.1002/jcb.28598

1. Koslowski, R., et al. (2003). Regulation of prolyl 4-hydroxylase alpha subunit expression by transforming growth factor-beta in human lung fibroblasts. European Journal of Biochemistry, 270(18), 3730–3738. https://doi.org/10.1046/j.1432-1033.2003.03756.x

1. Vasta, J. D., & Raines, R. T. (2015). Human prolyl 4-hydroxylase: A paradigm for the 2-oxoglutarate-dependent dioxygenases. Biochemistry, 54(31), 4783–4791. https://doi.org/10.1021/acs.biochem.5b00615

1. Myllyharju, J., & Kivirikko, K. I. (2004). Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends in Genetics, 20(1), 33–43. https://doi.org/10.1016/j.tig.2003.11.004

1. Gilkes, D. M., et al. (2013). Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Research, 73(11), 3285–3296. https://doi.org/10.1158/0008-5472.CAN-12-3963

1. Atkinson, A., et al. (2019). Structural basis for the inhibition of human prolyl 4-hydroxylase by small molecules. Journal of Biological Chemistry, 294(38), 13985–13997. https://doi.org/10.107